Full-Time
Senior Contracts Manager
Intuitive Surgical
10,001+ employees
Manufactures robotic surgical systems and services
No salary listed
Freiburg im Breisgau, Germany
In Person
Bachelor's
 Legal & Compliance (1) |
|---|
Get referred to Intuitive Surgical
See people who can refer or advise you
- Experience in negotiating key contractual terms and conditions.
- Knowledge of contract management best practices and commercial contract law.
- Ability to work under pressure, manage multiple projects simultaneously, and create and reset priorities as needed.
- Effective time management skills and demonstrate a positive and flexible attitude.
- Excellent verbal and written communication skills (German, French, and English) with ability to influence and persuade others.
- Ability to work independently and as part of a team
- Bachelor degree in law (e.g., erstes Staatsexamen / Diplom-Jurist / LLM).
- At least 10 years of relevant post-qualification legal or contract experience.
- Strong drafting skills, commercial mindset and attention to detail.
- Practical knowledge of GDPR and EU regulatory considerations relevant to contracts.
- Comfortable working with international contracts and cross-border transactions.
- Build strong relationships with key partners at different levels of the organization including legal, finance, and operations.
- Consult with Legal on key points of German and EU law and commercial best practice, interpreting complex terms and conditions, including IP related terms and incorporate their guidance into contract terms.
- Responsible for drafting, reviewing, and negotiating contracts that establish business relationships with suppliers.
- Analyze contracts to ensure compliance to company policy, government regulations, applicable laws, and other requirements.
- Analyze, interpret, and respond to terms presented in contracts.
- Negotiate contract terms and conditions with supplier.
- Provide guidance to internal stakeholders on contract terms, risk mitigation, and regulatory compliance.
- Develop and continuously improve contract templates, playbooks, and negotiation guidelines.
Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Sunnyvale, California
Founded
1995
Get referred to Intuitive Surgical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $2.89 billion, up 19%, with 70% gross margin.
- Europe direct operations started March 2, 2026, adding Italy, Spain, Portugal, and Malta.
- Ion procedures grew 36% in Q2 2026, expanding beyond da Vinci dependence.
What critics are saying
- FDA posted a Class II da Vinci 5 recall on February 18, 2026.
- Surgical Instrument Service and the FTC pressed Ninth Circuit antitrust claims on June 25, 2026.
- US da Vinci growth slowed to 12% in Q2 2026, threatening premium pricing.
What makes Intuitive Surgical unique
- Da Vinci 5 cleared for cardiac procedures on January 26, 2026.
- Intuitive owns 11,710 da Vinci and 1,096 Ion systems, creating switching costs.
- July 23, 2026 AI platform leverages 20 million procedures, unmatched surgical data scale.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.
Intuitive Surgical's stock has fallen 27% over the past twelve months, now trading 41% below its two-year high. The robotic surgery pioneer trades at 40.8 times earnings, the highest valuation in its sector. The company maintains a 31% operating margin, outpacing Johnson & Johnson's 27% and Medtronic's 18.8%. Revenue grew 21% over the last twelve months. The firm placed 468 da Vinci systems in the most recent quarter, an 18% increase year-over-year, driven by demand for its new da Vinci 5 platform. However, US procedure growth slowed to 12%, compared to 15% worldwide growth. Management attributed the slowdown to changes in patient coverage and premium dynamics causing treatment deferrals.
Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 19% year-on-year and beating Wall Street estimates. Despite this, shares fell 14.1% to a new 52-week low on Friday. The drop followed concerns about slowing US procedure volumes. Whilst global procedures grew 16%, growth for da Vinci systems in the critical US market moderated to 12%. Management noted that changes in patient coverage may be affecting demand for elective procedures. Paradoxically, capital equipment sales remained strong, with 468 da Vinci systems placed in the quarter, up 18% year-on-year. US placements jumped 24%, driven by the new da Vinci 5 platform. Management also detailed plans for an extended use programme launching in 2027, aimed at reducing costs but potentially impacting high-margin recurring revenue.
Intuitive Surgical reported strong Q2 results, with revenue up 19% year-over-year to $2.89 billion and non-GAAP earnings per share rising 28% to $2.80. Recurring revenue accounted for 85% of total sales. Total procedures increased 16%, driven by 15% growth in da Vinci procedures and 36% growth in Ion procedures. Whilst US growth slowed, international da Vinci procedures rose 20%, expanding across Europe and Asia. The company maintained its 2026 procedure outlook, keeping da Vinci procedure growth guidance at 13.5% to 15.5% whilst raising its non-GAAP gross margin forecast to 68% to 69%. Management highlighted continued demand for newer platforms including da Vinci 5, SP and Ion. The installed base grew to nearly 13,000 systems worldwide.
Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 18.5% year on year and beating Wall Street estimates of $2.82 billion. The medical technology company's non-GAAP profit of $2.80 per share exceeded analyst expectations by 11.9%. Despite the strong results, the stock declined. The drop was attributed to recent declines in overall surgery volumes reported by major healthcare providers and a Class II recall of certain da Vinci surgical components. Operating margin improved to 33.6%, up from 30.5% in the same quarter last year. Analysts expect revenue to grow 12.5% over the next 12 months, representing a deceleration from recent growth rates. The company has demonstrated solid long-term performance, with 16.4% annualised revenue growth over the past five years.